CUREAGE THERAPEUTICS LTD

Name

CUREAGE THERAPEUTICS LTD

Legal name

CureAge Therapeutics Ltd

Website

https://cureagetx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Genetic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)

Keywords

• Genetic medicine platform
• Lipid nanoparticle delivery
• Gene therapy development
• Peripheral nerve diseases
• Neurofibromatosis treatment

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Genetic Therapy Development and Commercialization: As a pre-clinical stage biotech company, CureAge does not currently generate revenue. The company is developing genetic medicines for NF1 and plans to commercialize therapies through licensing agreements with pharmaceutical partners or by building commercial infrastructure directly.

Go-to-market motion1 record

Marketing channels4 records

Core offering

CureAge Therapeutics develops a lipid nanoparticle (LNP)-based genetic medicine platform that delivers therapeutic genetic material directly to Schwann cells in peripheral nerves. Its lead program focuses on Neurofibromatosis Type 1 (NF1), using a dual-action payload that restores NF1 gene function while eliminating tumor cells, with the aim of producing the first curative therapy for peripheral nerve tumors delivered via a minimally invasive, localized approach.

Product overview

CureAge Therapeutics is a biotech company developing a genetic medicine platform using lipid nanoparticles (LNPs) for targeted delivery to Schwann cells. The core platform technology enables precise targeting of peripheral nerve cells through a novel local delivery approach. The lead program focuses on Neurofibromatosis type 1 (NF1), with the goal of developing the first curative therapy for peripheral tumors that can treat existing tumors, prevent new tumor formation, and provide long-lasting therapeutic benefit with minimal dosing.

Differentiator

Problem solved

Functional benefit

Products and services

• Genetic Medicine Platform for Peripheral Nerve Diseases A proprietary lipid nanoparticle (LNP) delivery platform combined with a novel in vivo local delivery approach that precisely targets Schwann cells in specific anatomical locations, using rationally designed payloads combining synergistic components into a dual-action mechanism. Serves as the foundation for all CureAge therapeutic programs targeting peripheral nerve diseases.
• NF1 Genetic Therapy Program A minimally invasive, LNP-delivered genetic therapy targeting tumor Schwann cells in Neurofibromatosis Type 1 (NF1) patients. Designed to restore NF1 gene function and eliminate surrounding tumor cells, with the goal of shrinking existing peripheral tumors, preventing new tumor formation, and providing a durable, potentially curative effect from only a few doses per year. Aimed at NF1 patients with peripheral nerve tumors for whom only two FDA-approved drugs exist, both with limited efficacy and significant side effects.

Quantifiable outcome

• Only two drugs currently approved for NF1 peripheral tumors, both with limited efficacy and high side effect-related dropout rates
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor.

• Charles River LaboratoriesminorStrategic or Co-development Partner · 1 December 2025Selected for Charles River's Global Cell & Gene Therapy Incubator Program (CIP) second cohort. The program provides access to Charles River's scientific expertise, regulatory guidance, and comprehensive development ecosystem spanning discovery to manufacturing. CureAge will benefit from tailored mentorship and preferential access to global cell and gene therapy development facilities.
• Weizmann Institute of ScienceminorStrategic or Co-development Partner · 1 January 2025Trusted research partner supporting CureAge's mission through David & Fela Shapell Family Foundation connection.
• IGTP (Institut Germans Trias i Pujol)minorStrategic or Co-development Partner · 1 January 2025Trusted partner with Eduard Serra, PhD serving as NF1 Advisor on CureAge's Scientific Advisory Board. IGTP's Hereditary Cancer Group brings over 25 years of NF1 research expertise.
• Penn (University of Pennsylvania)minorStrategic or Co-development Partner · 1 January 2025Trusted partner with Jake Brenner, MD, PhD serving as LNP Advisor on CureAge's Scientific Advisory Board. Dr. Brenner is Principal Investigator at UPenn Dept of Medicine pioneering novel LNP-based therapeutics.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Intellia Therapeutics: Intellia is a clinical-stage in vivo gene editing and gene therapy company using LNP delivery for CRISPR-based therapies, comparable to CureAge in non-viral delivery modality and rare disease focus, though applied to different tissue targets.
• NFlection Therapeutics: NFlection Therapeutics is a clinical-stage biotech developing therapies for Neurofibromatosis and related RASopathies, including topical and systemic agents for cutaneous and plexiform neurofibromas, making it a direct indication-matched peer.
• Lexeo Therapeutics: Lexeo is a clinical-stage genetic medicine company developing AAV and other gene therapies for rare diseases including neurological indications, making it directly comparable to CureAge in modality, stage, and orphan disease commercial strategy.
• Taysha Gene Therapies: Taysha is a clinical-stage gene therapy company focused on rare neurological diseases of the central and peripheral nervous system, with a platform approach analogous to CureAge's CNS/peripheral nerve franchise strategy.
• SpringWorks Therapeutics: SpringWorks developed and commercialized mirdametinib, one of the FDA-approved therapies for NF1-related plexiform neurofibromas, making it a direct competitor in NF1 peripheral tumor treatment and a key benchmark for CureAge's target market.
• Generation Bio: Generation Bio is a non-viral gene therapy company developing lipid nanoparticle-based delivery of genetic payloads for rare diseases, making it the closest platform peer to CureAge's LNP-Schwann cell delivery approach.
• Passage Bio: Passage Bio develops AAV-delivered gene therapies for rare monogenic diseases of the central nervous system, comparable to CureAge in genetic medicine modality, rare neurological disease focus, and partnership-driven development model.

Broad incumbents

• AstraZeneca: AstraZeneca markets selumetinib (Koselugo), one of the FDA-approved therapies for NF1, making it the most relevant large-pharma incumbent in CureAge's lead indication and a likely strategic partner or competitor for any NF1 approval.
• Alexion (AstraZeneca Rare Disease): Alexion is the rare disease unit of AstraZeneca with established commercial infrastructure for orphan neurological and genetic indications, directly relevant to CureAge's future commercial pathway and a likely partnership or acquisition counterparty.

Emerging players

• Beam Therapeutics: Beam is a clinical-stage base editing company using LNP and other non-viral delivery approaches for in vivo gene editing in rare and common diseases, overlapping with CureAge on delivery technology and rare disease strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cureage-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CUREAGE THERAPEUTICS LTD